Menu
Clinical Laboratory Director
A clinical pathologist with a subspecialty in molecular genetic pathology, Dr. Jensen oversees all clinical laboratory operations. He received his training from Northwell Health in New York and has a fellowship from the University of Washington in Seattle.
A prolific author in clinical and research areas, Dr. Jensen has published high-impact papers in JAMA Oncology and FASEB Journal. His research interests cover improving the quality and safety of genetic testing and structural variation analysis. While at the University of Washington, Dr. Jensen received editorial praise in JAMA Oncology for his work with Dr. Colin Pritchard in 2020.
Outside the lab, Dr. Jensen loves exploring nature and is a fan of art. He enjoys spending time with family, friends, dogs, and feathered friends – two conure parrots.
Jensen, K. Konnick E. Schweizer M. Sokolova, A. Grivas, P. Cheng, H. Klemfuss, N. Beightol, M. Yu, E.
Nelson, P. Montgomery, B. Pritchard, C. Association of Cloncal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference. JAMA Oncol. 2020. Nov 5;5e2505161. PMID: 33151258.
Jensen, K. Haniff, R. Kamarinos, A. Santiago, A. Rosenberg, A. Laser, J. Improving Turnaround Times by a
Series of Process Improvement Involving Barcoding, Floorplans, Staffing, Roche Analyzers, and a Second
Measuring Cell. J Appl Lab Med. 2019. Nov;4(3):311-322. PMID: 31659069
Jensen, K. Stallone, R. Eller, M. Castagnaro, J. Poczter, H. Tesoriero R, Balzano-Kane, Gusman, C. Bhuiya, T. Breining, D. Crawford, J. Northwell Health Laboratories: The 10-Year Outcomes after Deciding to Keep the Lab. Arch Pathol Lab Med. 2019, Dec;143(12):1517-1530. PMID: 31100013.
A pioneer in the science of detecting mis-folded proteins, Amprion advances the diagnosis of brain disorders. Our SYNTap™️ Biomarker Test aids physicians in diagnosing Parkinson’s, Lewy Body Dementia, and Alzheimer’s with Lewy Body variant. We plan to launch more biomarker tests in the future.
Amprion has some important news we need to share with you!
To improve patient access to the SYNTap® biomarker test (CSF), Amprion is reducing the self-pay price for tests with service dates on or after July 1, 2023.
Old self-pay price: $1500.00. New self-pay price: $995.00
Effective July 1, 2023, there is a New ABN (Advanced Beneficiary Notification) form for use when ordering the SYNTap® biomarker test (CSF) for patients on Medicare. Order Process
